NCRI Press Release, 8 November 2010
Date published: Nov 08 2010
Test selects 60 per cent of women with inherited ovarian cancer who could benefit from ‘smart’ drug
Download the attachment
Recent Tweets
-
Data from @SWOG highlights the impact of #COVID19 on enrollment in @theNCI sponsored clinical trials. https://t.co/14MOMucfy8
1 hour ago -
Study from @DanaFarber and @harvardmed suggests that patients with #Diabetes and #WeightLoss have high risk of deve… https://t.co/9g6naNP7E8
2 hours ago -
⏰ Last chance for cancer patients and carers to identify which questions they want answering on #cancer and… https://t.co/oONZAi5tS5
1 day ago
- 23 Jul 2020Applications welcome: Get Guidance on your Multidisciplinary Research Proposal
- 19 Mar 2020Workstream leads: NCRI Skin Group
- 26 Nov 2019CM-Path - Application for Consumer Membership (Deadline - 1st January 2020)
- 20 Nov 2019With its new chair, Professor David Harrison, at the helm, CM-Path share top priorities
- 19 Jul 2019Consumer (Patient / Carers) vacancies for NCRI Groups available. Apply today!
- 20 May 2019Celebrating ten years of NCRI’s Clinical and Translational Radiotherapy Research Group
- 29 Apr 2019NCRI and The British Society for Immunology announce new partnership
- 14 Mar 2019Register now for the NCRI CTU Annual Trials Meeting: 17 June 2019
RSS Feed